Jupiter Research Capital (Asia) Ltd’s Intellia Therapeutics NTLA Stock Holding History
Bought
Maintained
Sold
Other funds holding NTLA
Jupiter Research Capital (Asia) Ltd's NTLA Position: Q3 2026 in Review
Jupiter Research Capital (Asia) Ltd sold out of Intellia Therapeutics (NTLA) in Q3 2026, closing a stake of 13,649 shares — an estimated $231K sold.
Jupiter Research Capital (Asia) Ltd first reported a position in NTLA in Q1 2026 and held it in 2 quarters. The position peaked at $437K in Q1 2026. 284 funds tracked by Wall St. Rank hold NTLA as of Q3 2026.
- Jupiter Research Capital (Asia) Ltd reported no remaining Intellia Therapeutics position as of Q3 2026 after selling out during the quarter.
- Jupiter Research Capital (Asia) Ltd sold 13,649 Intellia Therapeutics shares in Q3 2026, an estimated $231K.
- Jupiter Research Capital (Asia) Ltd first reported a position in Intellia Therapeutics in Q1 2026 and held it in 2 quarters.
- Jupiter Research Capital (Asia) Ltd's Intellia Therapeutics position peaked at $437K in Q1 2026.
- 284 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2026.
Based on Jupiter Research Capital (Asia) Ltd's 13F filing for Q3 2026, filed 16 Nov 2026.